Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)

Piper Sandler analyst Chris Raymond reiterated an Overweight rating and $56.00 price target on Agios Pharma (NASDAQ: AGIO).

The analyst commented, "Remain OW rated on AGIO and VRTX shares and highlight herein a new hematologist survey (n=53) that we think bodes well for uptake of mitapivat and Casgevy in thalassemia and SCD. Lots of detail but with these indications representing by far the largest unmet need among hematologists, we like the commercial setup for both of these agents. Specific to mitapivat, awareness and willingness to prescribe are highest among all developmental agents in both thalassemia and SCD and docs’ most desired attributes would seem to play right into mitapivat’s strengths. Specific to Casgevy, feedback would seem to support VRTX’s narrative around moderate near-term uptake but sizable LT uptake potential, as docs indicate ~1/3 of SCD and TD-thal patients would ultimately be candidates for a gene therapy. Given this feedback we remain comfortable with our estimates for both mitapivat (well above consensus) and Casgevy (in-line, with major inflection beginning in 2026)."

For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.

Shares of Agios Pharma closed at $43.93 yesterday.

You May Also Be Interested In